|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00001123 |
The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.
Condition | Intervention |
Hantavirus Pulmonary Syndrome |
Drug: Ribavirin |
Drug Information available for: | Ribavirin |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
You may be eligible for this study if you:
Exclusion Criteria:
You will not be eligible for this study if you:
Study ID Numbers: | 95-066 |
First Received: | January 17, 2000 |
Last Updated: | November 11, 2005 |
ClinicalTrials.gov Identifier: | NCT00001123 |
Health Authority: | United States: Federal Government |
|
|
|
|